IN2014DN08829A - - Google Patents

Info

Publication number
IN2014DN08829A
IN2014DN08829A IN8829DEN2014A IN2014DN08829A IN 2014DN08829 A IN2014DN08829 A IN 2014DN08829A IN 8829DEN2014 A IN8829DEN2014 A IN 8829DEN2014A IN 2014DN08829 A IN2014DN08829 A IN 2014DN08829A
Authority
IN
India
Prior art keywords
growth factor
release profile
releasing
released
period
Prior art date
Application number
Other languages
English (en)
Inventor
Cameron M L Clokie
Sean A F Peel
Original Assignee
Induce Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2012/050234 external-priority patent/WO2012139223A1/en
Application filed by Induce Biolog Inc filed Critical Induce Biolog Inc
Publication of IN2014DN08829A publication Critical patent/IN2014DN08829A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
IN8829DEN2014 2012-04-11 2012-10-17 IN2014DN08829A (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CA2012/050234 WO2012139223A1 (en) 2011-04-11 2012-04-11 System and method for multiphasic release of growth factors
PCT/CA2012/050738 WO2013152418A1 (en) 2012-04-11 2012-10-17 System and method for multiphasic release of growth factors

Publications (1)

Publication Number Publication Date
IN2014DN08829A true IN2014DN08829A (https=) 2015-05-22

Family

ID=49328692

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8829DEN2014 IN2014DN08829A (https=) 2012-04-11 2012-10-17

Country Status (9)

Country Link
EP (1) EP2836195B1 (https=)
JP (1) JP6318143B2 (https=)
CN (2) CN104220046A (https=)
AU (1) AU2012376780B2 (https=)
CA (1) CA2868992C (https=)
ES (1) ES2873098T3 (https=)
IN (1) IN2014DN08829A (https=)
RU (1) RU2014145234A (https=)
WO (1) WO2013152418A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015374114B2 (en) * 2014-12-29 2018-07-26 Bioventus, Llc Systems and methods for improved delivery of osteoinductive molecules in bone repair
KR20180079368A (ko) 2015-10-30 2018-07-10 바이오벤터스 엘엘씨 골 복구에서 골유도 분자의 증진된 전달을 위한 매트릭스
EP3468626A1 (en) 2016-06-10 2019-04-17 Bioventus LLC Protein delivery with porous metallic structure
IL266008B (en) * 2016-10-17 2022-08-01 Lidds Ab A new method for producing calcium sulphate hemihydrate with unique properties
AU2018351687B2 (en) * 2017-10-19 2024-07-11 Genera Istrazivanja D.O.O. Autologous bone graft substitute

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761471A (en) 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4789732A (en) 1980-08-04 1988-12-06 Regents Of The University Of California Bone morphogenetic protein composition
US4795804A (en) 1983-08-16 1989-01-03 The Regents Of The University Of California Bone morphogenetic agents
US4857456A (en) 1985-04-30 1989-08-15 The Regents Of The University Of California Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US4877864A (en) 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5631142A (en) 1986-07-01 1997-05-20 Genetics Institute, Inc. Compositions comprising bone morphogenetic protein-2 (BMP-2)
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
CA2360938C (en) * 1999-02-02 2008-01-08 Warren Oliver Haggard Controlled release composite
US20070190102A1 (en) * 2000-06-30 2007-08-16 Ping Luo Method of preparing hydroxyapatite based drug delivery implant for infection and cancer treatment
US6503109B1 (en) 2000-07-19 2003-01-07 Marshall D. Duffield Swivel drive assembly
US6770695B2 (en) * 2000-08-07 2004-08-03 John L. Ricci Time release calcium sulfate matrix for bone augmentation
US20080233165A1 (en) * 2000-08-07 2008-09-25 Biolok International, Inc. Time release calcium sulfate and growth factor matrix for bone augmentation
US7671012B2 (en) * 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
EP1893174A2 (en) * 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
US20070248675A1 (en) * 2005-09-08 2007-10-25 Gwangju Institute Of Science And Technology Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof
US20070255422A1 (en) * 2006-04-25 2007-11-01 Mei Wei Calcium phosphate polymer composite and method
AU2009200540A1 (en) * 2008-07-03 2010-01-21 Induce Biologics Inc. Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness
US9492375B2 (en) * 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
WO2010017288A1 (en) 2008-08-05 2010-02-11 The University Of Miami Composite bone grafts, particulate bone-calcium sulfate constructs, and methods of treating joint injuries

Also Published As

Publication number Publication date
EP2836195B1 (en) 2021-03-10
JP6318143B2 (ja) 2018-04-25
JP2015516387A (ja) 2015-06-11
CA2868992A1 (en) 2013-10-17
WO2013152418A1 (en) 2013-10-17
CA2868992C (en) 2020-08-25
EP2836195A1 (en) 2015-02-18
EP2836195A4 (en) 2015-11-18
AU2012376780A1 (en) 2014-10-02
RU2014145234A (ru) 2016-05-27
CN104220046A (zh) 2014-12-17
AU2012376780B2 (en) 2017-11-23
CN110464701A (zh) 2019-11-19
ES2873098T3 (es) 2021-11-03

Similar Documents

Publication Publication Date Title
AU2012243410A8 (en) System and method for multiphasic release of growth factors
IN2014DN08829A (https=)
MX2022013590A (es) Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
MX2011007570A (es) Articulos absorbentes reusables para llevar puesto que tienen sistemas de fijacion.
ZA201504132B (en) Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
MX2011007576A (es) Articulos absorbentes reusables para llevar puestos con sistema secundario de fijacion.
NZ713029A (en) Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
MX2013014422A (es) Miembros y métodos de contacto de heridas.
GB2498145A (en) Releasable corrosion inhibitors
BR112014011381A2 (pt) artigos absorventes com sistemas de fixação por gancho e laço
WO2012037519A3 (en) Acceleration of wound healing by growth hormone releasing hormone and its agonists
CL2015001322A1 (es) Sistemas y métodos de cartílago triturado.
MX2014006136A (es) Uso de aril- y hetarilcarboxamidas como endoparasiticidas.
EP2529342A4 (en) SYSTEMS AND METHOD FOR MANAGING EVENTS
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
CY1123202T1 (el) Σκευασμα υδροκορτιζονης ελεγχομενης απελευθερωσης
IN2014DN10765A (https=)
IN2014CN04050A (https=)
PH12017500888A1 (en) Construction panel having improved fixing strength
MX341340B (es) Tratamiento con flama de substrato.
PH12015501297A1 (en) Composition and method for sustained release of agricultural macronutrients
MX351567B (es) Dispositivo de dispensación.
PH12013500882A1 (en) Pharmaceutical compositions
MX338646B (es) Sistema de suministro de fragancia de larga duracion.